

HEALTHCARE MONTHLY

JUNE 2021

Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies









BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSISIS
Medical Devices		 THE CARLYLE GROUP HELLMAN & FRIEDMAN	<ul style="list-style-type: none"> Blackstone (NYSE:BX), Carlyle Group (NasdaqGS:CG), and Hellman & Friedman have announced an agreement to acquire a majority stake in Medline Medline manufactures and distributes healthcare supplies and equipment used in hospitals, surgery centers, acute care and other medical facilities in more than 125 countries The acquiring private equity consortium collectively manages more than \$900 billion AUM Estimated Consideration: approximately \$34 billion enterprise value, including debt
Healthcare Services			<ul style="list-style-type: none"> Clayton, Dubilier & Rice entered into a definitive agreement to acquire UDG Healthcare (LSE:UDG) UDG Healthcare is a healthcare services provider that operates in two segments (i) integrated healthcare services and (ii) contract packaging, clinical, manufacturing and technology services Clayton, Dubilier & Rice is a private equity firm which has completed aggregate transactions valued at more than \$150 billion since inception Total Consideration: \$3.7 billion in cash (21% premium) Implied Enterprise Value: 3.0x LTM Revenue, 176x LTM EBITDA
BioTech / Pharma			<ul style="list-style-type: none"> The Carlyle Group (NasdaqGS:CG) entered into a definitive agreement to acquire Vectura Group plc (LSE:VEC) Vectura Group engages in the design, development, and supply of pharmaceutical products for the treatment of airway-related diseases The Carlyle Group is an investment firm specializing in direct and fund-of-fund investments, with more than \$260 billion AUM Total consideration: \$1.4 billion in cash (27% premium) Implied Enterprise Value: 4.0x LTM Revenue, 13.4x LTM EBITDA
			<ul style="list-style-type: none"> MorphoSys AG (NASDAQ:MOR) entered into a definitive agreement to acquire Constellation Pharmaceuticals (NasdaqGS:CNST) Constellation Pharmaceuticals develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance MorphoSys develops therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States Total consideration: \$1.4 billion in cash (68% premium)

HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index



123% BioTech / Pharma

140% Health Services

131% Life Sci / Diagnostics

130% Medical Devices

138% S&P 500 Index

SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Strongbridge Biopharma plc (Nasdaq:SBBP)	Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS)	Strongbridge Biopharma focuses on the development and commercialization of therapies for rare diseases Total consideration: \$275 million in cash and stock (12.9% premium)
Nexcelom Bioscience LLC (Ampersand)	PerkinElmer, Inc. (NYSE:PKI)	Nexcelom Bioscience develops cytometry products for cell analysis in biomedical research Total consideration: \$260 million in cash
Kuur Therapeutics Limited	Athenex, Inc. (NasdaqGS:ATNX)	Kuur Therapeutics engages in the development of CAR-NKT cell immunotherapies for the treatment of cancer Total consideration: \$185 million in cash

Target	Acquiror	Life Sci / Diagnostics Transactions
Inivata Limited	NeoGenomics Laboratories, Inc. (NasdaqCM:NEO)	Inivata operates as a clinical cancer genomics company researching circulating tumor DNA (ctDNA) to improve cancer testing Total consideration: \$390 million in cash
Vigene Biosciences, Inc.	Charles River Laboratories International, Inc. (NYSE:CRL)	Vigene Biosciences Inc. provides viral vector-based gene delivery systems for life science research, gene therapy, and cell therapy applications Total consideration: \$350 million in cash and milestones
HalioDx SAS	Veracyte, Inc. (NasdaqCM:VCYT)	HalioDx designs and develops in-vitro diagnostic products in the immuno-oncology field Total consideration: \$318 million in cash

Target	Acquiror	Health Services Transactions
Spire Healthcare (LSE:SPIT)	Ramsay Healthcare (ASX:RHC)	Spire Healthcare owns and operates private hospitals and clinics in the United Kingdom Total consideration: \$1.4 billion (24% premium) Implied EV: 2.2x LTM Revenue
Redmond Park Hospital, LLC	AdventHealth	Redmond Park Hospital operates a hospital that provides inpatient and outpatient programs in Georgia and Alabama Total Consideration: \$635 million in cash
Heart of Hospice, LLC	LHC Group, Inc. (NasdaqGS:LHCG)	Heart of Hospice owns and operates hospice centers in South Carolina, Arkansas, Louisiana, Mississippi, and Oklahoma

Target	Acquiror	Medical Device Transactions
Certain respiratory products of Teleflex Incorporated	Medline Industries, Inc.	The acquired respiratory product portfolio comprises oxygen and aerosol therapy, active humidification, non-invasive ventilation, and incentive spirometers Total consideration: \$274 million in cash
Proven Process Medical Devices, Inc.	NextPhase Medical Devices LLC (Kidd & Co)	Proven Process is a medical device design, development and manufacturing services firm
Distal Solutions, Inc.	Resonetics, LLC (GTCR)	Distal Solutions designs and develops catheter-based delivery systems and implants

Selected TM Capital Healthcare Experience

CHS
Canadian Hospital Specialists Ltd.
A PORTFOLIO COMPANY OF
CORTEC Group
HAS BEEN ACQUIRED BY
FLEXPOINT FORD

Empower
Community Care
HAS RECEIVED AN INVESTMENT FROM
NCP NORTHLANE
CAPITAL PARTNERS

\$65 MILLION
SERIES C EQUITY CAPITAL
CORISTA
HEALTH

TM Capital's Healthcare Industry Contacts



James McLaren
Managing Director
jmclaren@tmcapital.com
212.809.1414



Michael Goldman
Managing Director
mgoldman@tmcapital.com
212.809.1419



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com
212.809.1416



John Dean
Principal
jdean@tmcapital.com
404.995.6234



Steve Hunter
Managing Director, Sponsor Coverage
shunter@tmcapital.com
404.995.6232